Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation has issued its 2026 proxy statement for the May 28, 2026 virtual annual meeting, asking stockholders to elect two Class II directors, approve executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor.
For 2025, Glaukos reports net sales of $507 million and cash, equivalents, restricted cash and short-term investments of $283 million as of December 31, 2025. The eight‑member board is 88% independent, 38% women, and 25% from underrepresented communities, with an average age of 60.6 years and average tenure of 12.6 years.
The proxy highlights say‑on‑pay support of 97.7% at the 2025 meeting, a pay program emphasizing variable, performance‑linked compensation, stock ownership and clawback policies, and strong governance practices including overboarding limits, an updated code of conduct, active cybersecurity oversight, and expanding sustainability and climate initiatives.
Glaukos Corp’s chief development officer, Tomas Navratil, sold 2,093 shares of common stock in open‑market trades. The sales on April 10, 2026 were executed at prices ranging from about $116.72 to $120.23 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 12, 2026.
After these transactions, Navratil directly holds 90,370 shares of Glaukos common stock, which includes 39,791 restricted stock units that have not yet vested or been delivered. The filing notes that several trades were executed in multiple lots, with the reported prices reflecting weighted averages.
Glaukos Corporation submitted a Form 144 notice disclosing proposed sales of Common Stock by an affiliate through broker Fidelity Brokerage Services LLC. The filing lists past sales of 1,031 shares on 03/16/2026 for $101,085.67 and identifies restricted stock vesting events of 338, 517, and 1,238 shares on 12/13/2024, 12/18/2024, and 01/01/2025, respectively.
Glaukos Corp’s Chief Development Officer Tomas Navratil reported a routine tax-withholding disposition of 2,977 shares of common stock. The issuer withheld 1,146 shares and 1,831 shares at $109.60 per share to cover tax obligations upon vesting and delivery of restricted stock units granted in 2022 and 2024.
After these withholdings, Navratil directly owns 92,463 shares of common stock. His position also reflects 43,483 restricted stock units from the March 24, 2022 grant and 39,791 restricted stock units from the March 14, 2024 grant that have not yet vested or been delivered.
GLAUKOS Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported a routine tax-related share disposition. On the vesting and delivery of previously granted restricted stock units, the company withheld 1,589 shares of common stock to satisfy his tax withholding obligations.
After this non-market transaction, Thurman directly holds 43,681 shares of common stock. Footnotes also state he has 5,230 restricted stock units that have not yet vested or been delivered, indicating additional potential future equity awards.
GLAUKOS Corp president and COO Joseph E. Gilliam reported a routine tax-withholding share disposition tied to equity compensation. On the vesting and delivery of previously granted restricted stock units, 3,169 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations.
After this non-market transaction, he directly holds 92,992 shares of GLAUKOS common stock, including 43,925 restricted stock units that have not yet vested or been delivered. The filing does not reflect an open-market purchase or sale, but rather the automated tax treatment of stock-based compensation.
Glaukos Corp chairman and CEO Thomas William Burns reported non-market changes in his holdings. He transferred 180,308 shares of common stock as a bona fide gift from his direct ownership to the Burns Family Trust. Separately, a total of 9,937 shares were withheld by Glaukos at a price of $109.60 per share to satisfy his tax withholding obligations upon vesting and delivery of previously granted restricted stock units.
Following these transactions, Burns continues to hold common stock directly and indirectly through several trusts, and some of these positions include restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp Chief Development Officer Tomas Navratil reported a routine tax-withholding share disposition tied to restricted stock unit vesting. On March 31, 2026, 5,798 shares of common stock were withheld by the company at $109.60 per share to cover his tax obligations when RSUs granted on March 22, 2023 vested and were delivered. Following this withholding, he directly holds 95,440 shares, which includes 45,793 restricted stock units that are granted but have not yet vested or been delivered.
Glaukos Corp Chairman and CEO Thomas William Burns reported multiple equity compensation awards tied to performance goals. He received stock options covering 18,933 shares of common stock at an exercise price of $55.18 per share and 110,254 shares at $48.46 per share, reflecting portions of earlier performance-based grants that were earned after the board determined certain operational targets were achieved on March 25, 2026. He was also granted a new option for 98,474 shares at an exercise price of $109.60 per share, which vests over four years. In addition, he acquired 9,380 and 14,184 shares of common stock from performance-based restricted stock unit awards, with specified vesting in March and December 2026. Following these awards, he holds 263,271 common shares directly and maintains significant indirect holdings through various Burns family trusts.